Docebo Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Wednesday
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Updated: Nov 05 20250mins
Analyst Coverage Initiations: Oppenheimer's Ken Wong initiated coverage on Docebo Inc. (DCBO) with an Outperform rating and a price target of $35, while shares closed at $24.61.
Ascentage Pharma Rating: Piper Sandler's Biren Amin initiated coverage on Ascentage Pharma Group (AAPG) with an Overweight rating and a price target of $48, with shares closing at $33.25.
Vanda Pharmaceuticals Rating: B. Riley Securities' Madison El-Saadi initiated coverage on Vanda Pharmaceuticals Inc. (VNDA) with a Buy rating and a price target of $11, while shares closed at $4.35.
Market Overview: The article provides a snapshot of various stocks and their recent performance, highlighting analyst opinions and price targets for potential investors.
AAPG.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on AAPG
Wall Street analysts forecast AAPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG is 49.00 USD with a low forecast of 47.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.700
Low
47.00
Averages
49.00
High
51.00
Current: 30.700
Low
47.00
Averages
49.00
High
51.00
Oppenheimer
Matthew Biegler
Outperform
initiated
$45
2025-12-04
New
Reason
Oppenheimer
Matthew Biegler
Price Target
$45
2025-12-04
New
initiated
Outperform
Reason
Oppenheimer analyst Matthew Biegler initiated coverage of Ascentage Pharma with an Outperform rating and $45 price target. The firm believes Ascentage has the potential to become the next BeOne. To get there, they're taking a page from BeOne's playbook. Better drugs, focusing on chronic blood cancers with large TAMs, Oppenheimer argues, adding that olverembatinib looks like a best-in-class BCR-ABL inhibitor. Separately, Ascentage's BCL-2 inhibitor lisaftoclax is taking aim at BeOne's biggest market: Chronic Lymphocytic Leukemia. The firm believes lisaftoclax' tolerability could enable it to make inroads into an indication where other BCL-2 inhibitors have failed, namely Myelodysplastic syndrome.
Truist
Gregory Renza
Buy
initiated
$51
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$51
2025-11-24
initiated
Buy
Reason
Truist analyst Gregory Renza initiated coverage of Ascentage Pharma with a Buy rating and $51 price target. The company's Lisaftoclax is differentiated by improved tolerability and accelerated 5-day dose ramp-up, which is clinically meaningful, according to key opinion leaders, the analyst tells investors in a research note. Growth in China depends on the NRDL inclusion by the end of 2027, and the firm views GLORA's readout 2025-end or 2026E as key to supporting U.S. expansion in second-line CLL/SLL, or chronic lymphocytic leukemia/small lymphocytic lymphoma, the firm added.
BTIG
Buy
initiated
$50
2025-11-10
Reason
BTIG
Price Target
$50
2025-11-10
initiated
Buy
Reason
BTIG initiated coverage of Ascentage Pharma with a Buy rating and $50 price target. The firm says Ascentage has a "validated" apoptosis-targeted platform and two late-stage assets, Olverembatinib and Lisaftoclax, to drive sustained commercial growth and valuation upside. BTIG views Ascentage as one of the "most compelling" China-based biopharma stocks. The company is positioned to for "sustainable global relevance" as it transitions from clinical-stage to commercial-scale, the analyst tells investors in a research note.
Piper Sandler
Biren Amin
Overweight
initiated
$48
2025-11-05
Reason
Piper Sandler
Biren Amin
Price Target
$48
2025-11-05
initiated
Overweight
Reason
Piper Sandler analyst Biren Amin initiated coverage of Ascentage Pharma with an Overweight rating and $48 price target. The company's two approved assets in China are now under evaluation in the U.S., the analyst tells investors in a research note. Piper projects $1.9B and $1B in peak risk-adjusted global revenues for olverembatinib and lisaftoclax, respectively.
See All Ratings
About AAPG
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the purpose of Ascentage Pharma's investor webcast on December 11, 2025?
Why is the webcast being conducted in both English and Mandarin?
How might the Phase III trial results impact Ascentage Pharma's market valuation?
What are the potential financial implications of Takeda exercising its option agreement?